Anthrax

Reporting Obligations

Suspected cases must be reported immediately by phone to the Thunder Bay District Health Unit at 625-8318 or toll-free 1-888-294-6630, ext. 8318 (Monday-Friday, 8:30am to 4:30pm). After hours and on weekends/holidays call Nurses Registry Thunder Bay at (807) 624-1280. One case is deemed a public health emergency.

 

Epidemiology

Aetiologic Agent:

The aetiological agent of anthrax is the bacterium Bacillus anthracis (B. anthracis), an aerobic, Gram-positive, encapsulated, spore-forming, nonmotile rod. B. anthracis is a potential bioterrorist agent.

Clinical Presentation:

Depending on the route of transmission, anthrax infection can result in three clinical syndromes: cutaneous, inhalation and gastrointestinal.

Cutaneous anthrax is characterized by initial itching of the exposed skin surface; an initial vesicle at the site of inoculation develops into a painless black eschar; fever, malaise and headache may be present.

Inhalational anthrax is the most lethal form of disease. Initial presentation includes sweats, malaise, mild cough, dyspnea, nausea or vomiting, and this is followed by acute onset of respiratory distress and shock; there is also radiological evidence of mediastinal widening and pleural effusion present. The case fatality rate is extremely high. Anthrax meningitis begins with hypotension, quickly followed by delirium or coma; refractory seizures, cranial nerve palsies, and myoclonus have been reported.

Gastrointestinal anthrax cases present with acute vomiting, abdominal distension, gastrointestinal (GI) bleeding and peritonitis.

Modes of Transmission:

Transmission occurs by inoculation through open skin via contact with infected animal tissue, other animal products and contaminated soil and by ingestion of undercooked, contaminated or raw meat. Inhalation anthrax results from the inhalation of anthrax spores, particularly in risky industrial settings.

Incubation Period:

From 1-7 days, although incubation periods of up to 60 days are possible.

Period of Communicability:

Person to person transmission is rare. Articles and soil contaminated with spores may remain infective for years

 

Risk Factors/Susceptibility

There is some evidence of in-apparent infection among people in frequent contact with the infectious agent; second attacks can occur, but reports are rare.

  • Contact with animal skin/hide related products (rugs, drums etc.)
  • Deliberate use (bioterrorism)
  • Injection drug use
  • Occupational
    • Farm worker
    • Laboratory worker
    • Veterinarian
    • Animal or animal product handler

 

Diagnosis & Laboratory Testing

Laboratory demonstration of B. anthracis obtained from blood, CSF, pleural fluid, ascitic fluid, vesicular fluid or lesion exudates. Approved/Validated tests:

  • Standard culture for B. anthracis with confirmation
  • Direct fluorescent antibody (DFA) for B. anthracis
  • Nucleic acid amplification test (NAT) for B. anthracis

Testing Information & Requisition

 

Treatment & Case Management

One case is deemed a public health emergency. Cases may potentially signal a bioterrorism incident.

Public Health staff will be involved to obtain specific information to determine the source of infection and whether other cases may have been exposed. Persons who may have been exposed to anthrax are not contagious, so quarantine is not appropriate.

Persons with draining lesions should be cared for using contact precautions. Dressings with drainage from the lesions should be incinerated, autoclaved, or otherwise disposed of as biohazard waste.

 

Patient Information

Patient Fact Sheet

 

Additional Resources

1. Ministry of Health and Long-Term Care. “Health Care Professionals, Diseases: Anthrax”.

2. Heymann, D.L. Control of Communicable Disease Manual (20th Ed.). Washington, American Public Health Association, 2015. This resource provides in-depth information re: preventative measures, management of patient (including treatment), contacts and the immediate environment, as well as measures in case of deliberate use

3. PHAC. "Anthrax".

 

References

1. Ministry of Health and Long Term Care, Infectious Diseases Protocol, 2016. Appendix A (2014) and Appendix B (2014)

Last Updated: 26/10/2017